GEODON for INJECTION Rx
Generic Name and Formulations:
Ziprasidone (as mesylate) 20mg/mL; pwd for IM inj after reconstitution; preservative-free.
Indications for GEODON for INJECTION:
Rapid control of acute agitation.
10–20mg IM as needed, max 40mg/day (10mg every 2hrs; or 20mg every 4hrs); usual max 3 days. Switch to oral form as soon as possible.
History of QT prolongation. Congenital long QT syndrome. Recent acute MI. Uncompensated heart failure. Concomitant drugs that cause QT prolongation, including dofetilide, sotalol, quinidine, other Class Ia and III antiarrhythmics, mesoridazine, thioridazine, chlorpromazine, droperidol, pimozide, sparfloxacin, gatifloxacin, moxifloxacin, halofantrine, mefloquine, pentamidine, arsenic trioxide, levomethadyl, dolasetron, probucol, tacrolimus.
Increased mortality in elderly patients with dementia-related psychosis.
Increased mortality in elderly with dementia-related psychosis (not approved use). Concomitant use of oral and IM forms: not recommended. Renal (IM form) or hepatic impairment (both forms). Discontinue if QTc >500 msec persists, neuroleptic malignant syndrome, unexplained rash occurs, or if severe skin reactions (eg, Stevens-Johnson syndrome or DRESS) are suspected; consider discontinuing if tardive dyskinesia occurs. Conditions that increase risk of torsade de pointes (eg, bradycardia, hypokalemia, hypomagnesemia). Monitor potassium, magnesium, others if risk of electrolyte disturbances (eg, diarrhea); correct imbalance before starting. Avoid in significant cardiovascular disease (eg, arrhythmias). Evaluate cardiac function if symptoms of torsade de pointes occur (eg, dizziness, palpitations, syncope). Cardio- or cerebrovascular disease. Pre-existing low WBCs or history of leukopenia/neutropenia; monitor CBCs during 1st few months of treatment; discontinue if WBCs decline. Diabetes; monitor for hyperglycemia. Monitor weight. Risk of hypotension or seizures. History of breast cancer. Dysphagia. Exposure to extreme heat. Perform fall risk assessments when initiating and recurrently on long-term therapy. Reevaluate periodically. Write ℞ for smallest practical amount. Neonates: risk of extrapyramidal and/or withdrawal symptoms post delivery (due to exposure during 3rd-trimester pregnancy). Labor & delivery. Pregnancy (Cat.C). Nursing mothers: not recommended.
Serotonin and dopamine antagonist.
See Contraindications. May potentiate CNS drugs, antihypertensives. May antagonize levodopa, dopamine agonists. Extent of absorption and/or plasma levels may be affected by CYP3A4 inducers (eg, carbamazepine) or inhibitors (eg, ketoconazole). Correct hypokalemia, hypomagnesemia due to diuretics.
Somnolence, extrapyramidal syndrome, respiratory disorder, dizziness, akathisia, abnormal vision, asthenia, vomiting, nausea, rash, dystonia, postural hypotension, QTc prolongation, headache, weight gain, inj site reactions, hyperprolactinemia, dyslipidemia, hyperglycemia; rare: priapism, leukopenia, neutropenia, agranulocytosis (may be fatal).
Caps—60; Single-use vials—10
Sign Up for Free e-newsletters
- Is Radioimmunotherapy a Path Forward for Melanoma?
- FDA Approves Mogamulizumab-kpkc for Rare Subtypes of Non-Hodgkin Lymphoma
- New PDL1 Inhibitors for Non-small Cell Lung Cancer: Focus on Pembrolizumab
- Intensive Chemotherapy May Not Be Effective in MDS or AML After MDS
- ASCO Endorses SIO Guideline for Integrative Therapies in Breast Cancer
- NCCIH HerbList App Launched to Provide Information on Herbal Products
- Metformin Use May Improve Survival Outcomes in Bladder Cancer
- Higher Vitamin D Levels Associated With Lower Breast Cancer Risk
- Nurse-Led Program Improves Health, Financial Outcomes in Outpatient Chemotherapy
- Seeking Reliable Information on Herbal Products
- Disparities Remain in Prevalence of Cancer Screening Tests
- Hope, Gratitude, and Spirituality: What They Mean to Cancer Patients
- FDA, EU Approvals Sought for Split Dose Regimen of Daratumumab for Multiple Myeloma
- 8 Hours of Bedrest May Be Ideal After Intrathecal Chemotherapy in Hematologic Cancers
- Combined Digital Screening Best for Detecting Breast Cancers
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|